Flex Pharma, Inc. (FLKS) financial statements (2021 and earlier)

Company profile

Business Address 2450 HOLCOMBE BLVD
HOUSTON, TX 77021
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4477101316
Cash and cash equivalents4477101316
Restricted cash and investments    0  
Receivables  00000
Inventory, net of allowances, customer advances and progress billings  00000
Inventory  00000
Prepaid expense11     
Other current assets00     
Other undisclosed current assets0001001
Total current assets:5578101417
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)99     
Goodwill99     
Other noncurrent assets00     
Other undisclosed noncurrent assets     00
Total noncurrent assets:9900000
TOTAL ASSETS:141478101417
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2211122
Accounts payable2210011
Accrued liabilities  01000
Employee-related liabilities  00000
Deferred revenue12  
Debt11     
Deferred rent credit     00
Derivative instruments and hedges, liabilities00     
Restructuring reserve    001
Due to related parties 0     
Other undisclosed current liabilities    012
Total current liabilities:3411134
Noncurrent Liabilities
Liabilities, other than long-term debt      0
Deferred rent credit      0
Total noncurrent liabilities:      0
Other undisclosed liabilities00     
Total liabilities:3511134
Stockholders' equity
Stockholders' equity attributable to parent11106791113
Common stock0000000
Additional paid in capital2320143142142142142
Accumulated deficit(12)(10)(137)(135)(133)(131)(128)
Total stockholders' equity:11106791113
TOTAL LIABILITIES AND EQUITY:141478101417

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues1100000
Net investment income  00000
Cost of revenue
(Cost of Goods and Services Sold)
  (0)(0)(0)(0)(0)
Gross profit:1100000
Operating expenses(3)(5)(2)(2)(2)(3)(9)
Other undisclosed operating income  00000
Operating loss:(2)(4)(1)(2)(2)(3)(9)
Net loss:(2)(4)(1)(2)(2)(3)(9)
Other undisclosed net income attributable to parent0100000
Net loss available to common stockholders, diluted:(2)(3)(1)(2)(2)(3)(9)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(2)(4)(1)(2)(2)(3)(9)
Comprehensive loss:(2)(4)(1)(2)(2)(3)(9)
Other undisclosed comprehensive income, net of tax, attributable to parent  00000
Comprehensive loss, net of tax, attributable to parent:(2)(4)(1)(2)(2)(3)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: